1. Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine;Allan J. D.;Clin. Infect. Dis.,1993
2. Barditch P. B. Polsky C. van der Horst F. Ducanson O. Kuye D. Ganes R. Faulkner R. Raasch D. Armstrong B. Petty B. Rae A. Yacobi C. Flexner and R. Desjardins. 1992. Hematologic toxicity of FLT appears to be AUC dependent. Clin. Pharm. Ther. 51:170 abstr. Oll-1).
3. Barditch-Crovo P. D. Ganes F. Duncanson C. van der Horst B. Polsky B. Petty R. Faulkner O. Kuye A. Yacobi P. Lietman C. Norden and C. Flexner. 1992. Early markers of hematologic toxicity with FLT therapy abstr. WeB 1012 p. We 47. In Abstract book vol. 1. VIII International Conference on AIDS/III STD World Congress. Harvard AIDS Institute Cambridge.
4. Hematological complications of antiinfectious agents;Beris P.;Semin. Hematol.,1988
5. Blum M. R. S. H. T. Liao S. S. Good and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85(Suppl. 2A):189-194.